JCM Figure table search 04
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Argüelles, M. H.
Right arrow Articles by Glikmann, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Argüelles, M. H.
Right arrow Articles by Glikmann, G.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, August 2006, p. 2733-2738, Vol. 44, No. 8
0095-1137/06/$08.00+0     doi:10.1128/JCM.00980-05
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

Measles Virus-Specific Antibody Levels in Individuals in Argentina Who Received a One-Dose Vaccine

Marcelo H. Argüelles,1,2 Mariana L. Orellana,1,3 Alejandro A. Castello,1 Guillermo A. Villegas,4 Matilde Masini,1 Alejandra L. Belizan,1,3 Silvia González Ayala,5 Osmar D. Vera,1 and Graciela Glikmann1*

Laboratorio de Inmunología y Virología, Departamento de Ciencia y Tecnología, Universidad Nacional de Quilmes,1 Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET),2 Agencia Nacional de Promoción Científica y Tecnológica (ANPCyT),3 Centro de Virología Animal (CEVAN), Buenos Aires,4 Servicio de Infectología, Hospital de Niños Sor María Ludovica, La Plata, Argentina5

Received 17 May 2005/ Returned for modification 4 January 2006/ Accepted 8 June 2006

In spite of active measles virus (MV) vaccination strategies, reemergence continues to occur, impairing global eradication programs. The immune status against measles was evaluated in 350 vaccinated healthy Argentine children and teenagers who received a single dose of the MV Schwarz strain Lirugen vaccine (Aventis Pasteur). Sera were assessed for immunoglobulin G (IgG) antibodies by a commercial enzyme immunoassay (EIA) (Enzygnost; Behring), an in-house EIA, and neutralization EIA. Results obtained with these methods showed a marked decline in IgG level with increasing age. At 1 to 4 years of age, 84% of children had IgG antibodies above 200 mIU/ml, conventionally accepted as protective levels, whereas only 32% of older children and teenagers had antibody levels exceeding 200 mIU/ml. Moreover, the MV IgG content in the teenage group was significantly lower than the IgG antibody level of the group of younger children (P < 0.0001). In contrast, screening for IgG antibody levels to inactivated tetanus vaccine showed that, on average, 80% of this population was fully protected and that this high level of protection remained through the teenage years. This study suggests that within this population a considerable proportion of individuals had low measles antibody levels that may be insufficient to protect against reinfections or clinical disease.

* Corresponding author. Mailing address: Laboratorio de Inmunología y Virología, Departamento de Ciencia y Tecnología, Universidad Nacional de Quilmes, Roque Sáenz Peña 352, Bernal (B1876BXD), Buenos Aires, Argentina. Phone: 54 11 4365 7100, ext. 163. Fax: 54 11 4365 7132. E-mail: gglikman{at}unq.edu.ar.

Journal of Clinical Microbiology, August 2006, p. 2733-2738, Vol. 44, No. 8
0095-1137/06/$08.00+0     doi:10.1128/JCM.00980-05
Copyright © 2006, American Society for Microbiology. All Rights Reserved.





Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Antimicrob. Agents Chemother. Clin. Microbiol. Rev.
Clin. Vaccine Immunol. ALL ASM JOURNALS

Copyright © 2006 by the American Society for Microbiology. All rights reserved.